Please assess the completion status of the following clinical trial:

Trial Title: Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of essential hypertension~* Treating physician has determined that pharmacologic therapy is necessary~Exclusion Criteria:~* Compelling indication to select one particular medication~* Specific contraindication for any of the 3 therapies

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine, then HCTZ, then Lisinopril (Type: ACTIVE_COMPARATOR): Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- Amlodipine, then Lisinopril, then HCTZ (Type: ACTIVE_COMPARATOR): Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- HCTZ, then Amlodipine, then Lisinopril (Type: ACTIVE_COMPARATOR): Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- HCTZ, then Lisinopril, then Amlodipine (Type: ACTIVE_COMPARATOR): Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- Lisinopril, then Amlodipine, then HCTZ (Type: ACTIVE_COMPARATOR): Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- Lisinopril, then HCTZ, then Amlodipine (Type: ACTIVE_COMPARATOR): Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.

Based on this trial design, predict the completion outcome and termination type (if applicable).